Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies

por Jacqmin, P, Wade, J R, Weatherley, B, Snoeck, E, Marshall, S, McFadyen, L
Publicado 2013

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optim...

por Lewis, ME, Simpson, P, Mori, J, Jubb, B, Sullivan, J, McFadyen, L, van der Ryst, E, Craig, C, Robertson, DL, Westby, M
Publicado 2021